T. Rowe Price Associates’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $396K | Buy |
44,743
+4,393
| +11% | +$38.9K | ﹤0.01% | 2409 |
|
|
2025
Q1 | $316K | Buy |
40,350
+3,677
| +10% | +$28.8K | ﹤0.01% | 2446 |
|
|
2024
Q4 | $386K | Buy |
36,673
+6,445
| +21% | +$67.8K | ﹤0.01% | 2386 |
|
|
2024
Q3 | $397K | Buy |
30,228
+837
| +3% | +$11K | ﹤0.01% | 2348 |
|
|
2024
Q2 | $0 | Buy |
+29,391
| New | – | ﹤0.01% | 2933 |
|
|
2023
Q3 | – | Sell |
-127,293
| Closed | -$2.1M | – | 2889 |
|
|
2023
Q2 | $2.1M | Buy |
+127,293
| New | +$2.1M | ﹤0.01% | 1456 |
|
|
2015
Q2 | – | Sell |
-1,131,500
| Closed | -$20.3M | – | 2536 |
|
|
2015
Q1 | $20.3M | Buy |
1,131,500
+3,500
| +0.3% | +$62.9K | ﹤0.01% | 1127 |
|
|
2014
Q4 | $19.3M | Buy |
1,128,000
+665,900
| +144% | +$11.4M | ﹤0.01% | 1123 |
|
|
2014
Q3 | $6.61M | Buy |
+462,100
| New | +$6.61M | ﹤0.01% | 1410 |
|